Anti-BCAP29 / B-cell receptor-associated protein 29

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. The BCAP29 antibody targets B-cell receptor-associated protein 29, a membrane-associated chaperone encoded by the BCAP29 gene. B-cell receptor-associated protein 29 localizes mainly to the endoplasmic reticulum (ER) and Golgi apparatus, where it functions in protein trafficking, quality control, and ER-to-Golgi transport. It forms part of a complex with BCAP31, facilitating the export of membrane and secretory proteins. The BCAP29 antibody provides a powerful research tool for examining intracellular trafficking, membrane-protein maturation, and immune signaling. B-cell receptor-associated protein 29 contributes to proper folding and assembly of multimeric proteins in the ER. It interacts with several chaperone components, including Sec61 and calnexin, to ensure accurate post-translational processing before cargo delivery to the Golgi. The BCAP29 antibody supports localization studies demonstrating its distribution along ER membranes and cis-Golgi compartments. Through its cooperation with BCAP31, it links cargo transport with apoptotic signaling under stress conditions. In B lymphocytes, B-cell receptor-associated protein 29 participates in antigen receptor processing and trafficking. The BCAP29 antibody enables investigation of these processes and provides insight into how ER quality control affects immune-receptor assembly. It is also expressed in non-immune cells, indicating a more general role in secretory-pathway regulation. Disruption of BCAP29 function has been associated with altered membrane trafficking and ER stress responses. Emerging evidence suggests B-cell receptor-associated protein 29 may modulate apoptosis and calcium homeostasis. Its interaction with the pro-apoptotic regulator BCL2 family proteins suggests that BCAP29 may act as a mediator between ER stress and mitochondrial signaling. The BCAP29 antibody allows researchers to study these molecular connections in models of neurodegeneration, immune activation, and cancer. The BCAP29 antibody performs effectively in western blotting, immunofluorescence, and immunohistochemistry, producing characteristic perinuclear staining consistent with ER localization. NSJ Bioreagents provides this antibody as a validated, high-specificity reagent suitable for cell biology, immunology, and molecular research. By enabling precise detection of B-cell receptor-associated protein 29, the BCAP29 antibody advances understanding of ER quality control, trafficking regulation, and the interplay between membrane transport and apoptotic pathways.